Look up any medication to see its FAA medical certification status, pathway requirements, and practical guidance for pilots. Based on publicly available FAA guidance including the AME Guide and Do-Not-Issue/Do-Not-Fly tables.
These medications are generally compatible with FAA medical certification. Your AME can typically issue your certificate at the time of exam.
Zestril, Prinivil
Lisinopril and other ACE inhibitors are generally compatible with FAA medical certification. Most AMEs can issue your certificate at the time of exam if blood pressure is well-controlled and there are no significant side effects.
View details →Norvasc
Amlodipine is generally acceptable for FAA medical certification. As a peripheral-acting calcium channel blocker, it is not on the Do Not Issue list. Report it on your application and ensure blood pressure is controlled.
View details →Lipitor
Atorvastatin and other statin medications are generally compatible with FAA medical certification. AMEs can typically issue certificates at the time of exam. Report the medication on your application and note any side effects.
View details →Lopressor, Toprol-XL
Metoprolol is generally acceptable for pilots when used for hypertension. The underlying cardiac condition being treated may require additional evaluation. Beta blockers used post-cardiac event require Special Issuance.
View details →Cozaar
Losartan and other ARBs (angiotensin receptor blockers) are generally compatible with FAA medical certification for hypertension treatment.
View details →Prilosec
Omeprazole and other PPIs are generally acceptable for FAA medical certification when used for GERD or acid reflux. The underlying condition should be stable and not cause symptoms that could impair flight safety.
View details →Synthroid, Levoxyl
Levothyroxine for hypothyroidism is generally compatible with FAA certification. Pilots must demonstrate stable thyroid levels (TSH within normal range) and be free of symptoms.
View details →Advil, Motrin
Ibuprofen is generally acceptable for pilots when used as directed. The FAA primarily requires that the underlying condition being treated does not itself disqualify you, and that you are not experiencing side effects that affect flight safety.
View details →Tylenol
Acetaminophen is one of the most commonly used OTC medications among pilots. It is generally acceptable with no required wait time, provided the underlying condition being treated is not disqualifying.
View details →Claritin
Loratadine is generally the preferred antihistamine for pilots. Non-sedating in most individuals, but the FAA still recommends a ground trial before flying to confirm no individual sedation response.
View details →Zocor
Simvastatin is generally compatible with FAA certification. Same pathway as other statins — report it, ensure no significant muscle-related side effects.
View details →Crestor
Rosuvastatin is generally compatible with FAA medical certification. Like other statins, report the medication and ensure no significant muscle-related side effects such as rhabdomyolysis.
View details →Pravachol
Pravastatin is generally compatible with FAA certification. It has a lower risk of muscle-related side effects compared to some other statins, making it a common choice among pilots.
View details →Vasotec
Enalapril is an ACE inhibitor generally compatible with FAA medical certification. Blood pressure must be well-controlled and the pilot should not experience significant side effects such as dizziness or persistent cough.
View details →Altace
Ramipril is an ACE inhibitor acceptable for FAA certification when blood pressure is controlled. Report any side effects such as dizziness or dry cough to your AME.
View details →Lotensin
Benazepril is an ACE inhibitor generally compatible with FAA certification. Same pathway as other ACE inhibitors — report the medication and ensure blood pressure is well-controlled.
View details →Diovan
Valsartan is an ARB generally compatible with FAA medical certification for hypertension. Report on your application and ensure blood pressure is controlled.
View details →Avapro
Irbesartan is an ARB acceptable for FAA certification. Like other ARBs, it is not on the Do Not Issue list and AMEs can issue certificates when blood pressure is well-controlled.
View details →Benicar
Olmesartan is an ARB generally compatible with FAA certification. Standard antihypertensive pathway applies — report medication and demonstrate controlled blood pressure.
View details →Atacand
Candesartan is an ARB acceptable for FAA medical certification. Report on your application and ensure blood pressure is well-controlled with no significant side effects.
View details →Micardis
Telmisartan is an ARB generally compatible with FAA certification. Same pathway as losartan and other ARBs — report and demonstrate controlled blood pressure.
View details →Cardizem, Tiazac
Diltiazem is a calcium channel blocker generally acceptable for FAA certification when used for hypertension. If prescribed for arrhythmia, the underlying cardiac condition may require Special Issuance evaluation.
View details →Procardia, Adalat
Nifedipine is a calcium channel blocker generally acceptable for FAA certification. As a peripheral vasodilator, it is preferred over centrally-acting antihypertensives. Report on your application.
View details →Calan, Verelan
Verapamil is generally acceptable for FAA certification when used for hypertension. Like diltiazem, if prescribed for arrhythmia control, the underlying condition may require additional evaluation.
View details →Tenormin
Atenolol is a beta blocker generally acceptable for pilots when prescribed for hypertension. Like metoprolol, if used post-cardiac event or for arrhythmia, Special Issuance may be required.
View details →Inderal
Propranolol is a non-selective beta blocker generally acceptable for FAA certification when used for hypertension. If prescribed for performance anxiety, tremor, or migraine prevention, discuss the underlying indication with your AME.
View details →Coreg
Carvedilol is acceptable for FAA certification when used for hypertension. However, it is commonly prescribed for heart failure, which itself requires Special Issuance evaluation. The indication matters significantly.
View details →Zebeta
Bisoprolol is a selective beta blocker generally acceptable for FAA certification when used for hypertension. Report the medication and ensure no exercise intolerance or symptomatic bradycardia.
View details →Bystolic
Nebivolol is a newer selective beta blocker acceptable for FAA certification. It may have fewer fatigue-related side effects than older beta blockers, making it popular among active pilots.
View details →Microzide, HydroDIURIL
Hydrochlorothiazide (HCTZ) is one of the most commonly used diuretics and is generally acceptable for FAA certification. Pilots should be aware of electrolyte imbalances and dehydration risk, especially in hot cockpit environments.
View details →Lasix
Furosemide is generally acceptable for FAA certification, but the underlying condition requiring a loop diuretic (heart failure, edema) may require Special Issuance. The medication itself is not on the DNI list.
View details →Aldactone
Spironolactone is not on the FAA's Do Not Issue list and may be acceptable for certification. The underlying condition (heart failure, hypertension, hormonal) drives the certification pathway. Report medication and indication.
View details →Thalitone
Chlorthalidone is a thiazide-like diuretic acceptable for FAA certification. Like HCTZ, it is commonly used for hypertension and is not on the Do Not Issue list. Monitor electrolytes and hydration.
View details →Protonix
Pantoprazole is a PPI generally acceptable for FAA certification. Like omeprazole, ensure the underlying GI condition is stable and not causing symptoms that could impair flight safety.
View details →Prevacid
Lansoprazole is a PPI acceptable for FAA certification. Same pathway as omeprazole — report the medication and ensure the underlying condition is well-managed.
View details →Nexium
Esomeprazole is a PPI generally acceptable for FAA certification. Report it on your application and ensure the underlying GERD or acid reflux is well-controlled.
View details →Aciphex
Rabeprazole is a PPI acceptable for FAA medical certification. Same pathway as other PPIs — the medication itself is not an issue; focus is on the underlying GI condition being well-controlled.
View details →Pepcid
Famotidine is an H2 blocker available over the counter and is generally acceptable for pilots. It does not cause sedation and is commonly used for heartburn and GERD. Report on your application.
View details →Zantac (discontinued)
Ranitidine was an H2 blocker previously acceptable for pilots. It was withdrawn from most markets in 2020 due to NDMA contamination concerns. If still in use outside the US, same pathway as famotidine applies.
View details →Tapazole
Methimazole for hyperthyroidism is generally compatible with FAA certification once thyroid function is stable and within normal range. The pilot must be free of symptoms such as tremor, palpitations, or heat intolerance.
View details →Bayer Low-Dose, Baby Aspirin
Low-dose aspirin (81mg) for cardiovascular prevention is generally acceptable for pilots. The underlying cardiovascular condition being managed may require additional evaluation, but the medication itself is not an issue.
View details →Plavix
Clopidogrel is not on the FAA DNI list and is generally acceptable. However, the underlying condition requiring antiplatelet therapy (coronary stent, stroke prevention) typically requires Special Issuance evaluation.
View details →Zyloprim
Allopurinol for gout prevention is generally compatible with FAA certification. The medication is not on the DNI list. Ensure gout is well-controlled and not causing acute flares that could impair flight duties.
View details →Colcrys, Mitigare
Colchicine for gout treatment and prevention is generally acceptable for FAA certification. During an acute gout flare, pilots should not fly due to pain and mobility impairment rather than the medication itself.
View details →Amoxil, Trimox
Amoxicillin is generally acceptable for pilots. The key consideration is the underlying infection being treated — pilots should not fly while acutely ill. Once feeling well and infection is resolving, flying is typically permissible.
View details →Zithromax, Z-Pack
Azithromycin is generally acceptable for pilots. The underlying infection is the primary concern. Do not fly while acutely ill. Once symptoms resolve and you are feeling well, flying is typically permissible.
View details →Cipro
Ciprofloxacin is generally acceptable for FAA certification. However, fluoroquinolones can cause tendon issues, CNS effects, and peripheral neuropathy. Pilots should complete the course and ensure no significant side effects before flying.
View details →Vibramycin, Doryx
Doxycycline is generally acceptable for pilots. Commonly used for infections and malaria prophylaxis. Sun sensitivity is the main side effect concern for pilots. Ensure no dizziness or visual disturbance.
View details →Keflex
Cephalexin is generally acceptable for pilots. A first-generation cephalosporin with minimal CNS effects. The underlying infection is the primary concern for flight safety, not the medication itself.
View details →Levaquin
Levofloxacin is generally acceptable for FAA certification with the same precautions as ciprofloxacin. Monitor for CNS effects, tendon issues, and peripheral neuropathy. Ground trial recommended before flying.
View details →Diflucan
Fluconazole is generally acceptable for pilots for short-term antifungal treatment. No significant CNS effects at standard doses. The underlying condition should not impair flight safety.
View details →Viagra, Revatio
Sildenafil is acceptable for FAA certification with a mandatory 8-hour wait period after each dose. Pilots must not fly within 8 hours of taking a dose due to potential visual disturbances (blue-tinted vision) and hemodynamic effects.
View details →Cialis, Adcirca
Tadalafil is acceptable for FAA certification with a mandatory wait period. For as-needed use, a 24-hour wait is required. For daily low-dose use (2.5mg or 5mg), a 7-day ground trial is required to ensure no adverse effects before flying.
View details →Aleve, Naprosyn
Naproxen is generally acceptable for pilots when used as directed. Like ibuprofen, the underlying condition being treated is the primary concern. No specific grounding period for occasional use.
View details →Bayer, Bufferin, Ecotrin
Aspirin is generally acceptable for pilots for both pain relief and cardiovascular prophylaxis. No specific grounding period. The underlying condition being treated is the primary consideration.
View details →Sudafed
The FAA lists pseudoephedrine (Sudafed) as an acceptable decongestant, alone or in combination products, with no post-dose no-fly time once you have completed a 48-hour ground trial after first using it. It can speed up your heart rate, so use caution if you have a heart condition, and be careful about adding extra caffeine. Check combination products — many nighttime or "PM" formulas also contain a sedating antihistamine.
View details →Mucinex, Robitussin
Guaifenesin is an expectorant generally acceptable for pilots. It has no sedating properties when used alone. However, many combination products contain additional ingredients (dextromethorphan, antihistamines) that may affect flying.
View details →Singulair
The FAA lists montelukast (Singulair) as an acceptable allergy medication, and the CACI Asthma Worksheet lists leukotriene receptor antagonists such as montelukast as acceptable for asthma. When you first start it, the FAA requires a 48-hour ground trial with no side effects before you fly. If you take it for asthma, your AME can issue only if your asthma meets the CACI criteria, including limits on symptoms and rescue inhaler use.
View details →Wegovy
As of the FAA's August 26, 2026 weight loss medication update, semaglutide (Wegovy, injection or oral) is acceptable for weight loss when certification criteria are met: an A1C of 6.4 or less, no diagnosis of diabetes, and no history of hypoglycemia requiring intervention. Do not fly for one week after starting, or for 48 hours after any dose increase or formulation change. If you take semaglutide for diabetes (Ozempic, Rybelsus), the diabetes Special Issuance pathway applies instead.
View details →Allegra
Fexofenadine is a second-generation antihistamine generally acceptable for pilots. It is non-sedating in most individuals. A ground trial is recommended to confirm no individual sedation response.
View details →Proscar, Propecia
Finasteride for BPH or hair loss is generally compatible with FAA certification. The medication has no significant CNS effects and is not on the DNI list. Report on your application.
View details →Flomax
Tamsulosin for benign prostatic hyperplasia is generally acceptable for FAA certification. The main concern is orthostatic hypotension (dizziness upon standing), which should be assessed during ground trial.
View details →Cardura
Doxazosin is generally acceptable for FAA certification when used for BPH or hypertension. The main aviation concern is orthostatic hypotension (dizziness on standing). A ground trial is recommended.
View details →Zetia
Ezetimibe is generally compatible with FAA certification. Used alone or with statins for cholesterol management, it has a favorable side effect profile and is not on the DNI list.
View details →TriCor, Fenoglide
Fenofibrate for triglyceride management is generally compatible with FAA certification. Report the medication and ensure no significant side effects, particularly muscle pain when used with statins.
View details →Flagyl
Metronidazole is generally acceptable for pilots for short-term use. The main concern is the underlying infection. Avoid alcohol while on metronidazole due to severe interaction. Some pilots report metallic taste and mild nausea.
View details →Bactrim, Septra
TMP-SMX (Bactrim) is generally acceptable for pilots. The underlying urinary tract or other infection is the primary concern. Ensure adequate hydration and no significant side effects before flying.
View details →Macrobid, Macrodantin
Nitrofurantoin is generally acceptable for pilots for UTI treatment. Minimal systemic effects. The underlying infection is the primary concern for flight safety.
View details →Flonase, Veramyst
Fluticasone nasal spray is generally acceptable for pilots. It is a topical corticosteroid with minimal systemic absorption. No wait period or grounding required.
View details →Nasonex
Mometasone nasal spray is generally acceptable for pilots. Like fluticasone nasal, it is a topical corticosteroid with minimal systemic effects and no grounding requirement.
View details →Imodium
Loperamide is generally acceptable for pilots for short-term diarrhea management. The underlying GI condition is more important. Do not fly while experiencing active gastrointestinal illness.
View details →Prilosec OTC
OTC omeprazole is acceptable for pilots, same as prescription omeprazole. Report even OTC medications on your application. The underlying GERD should be well-controlled.
View details →Zovirax, Sitavig
Acyclovir for herpes simplex or herpes zoster is generally acceptable for FAA certification. The medication has minimal CNS effects. The underlying condition (particularly if involving the eye or causing significant pain) should be assessed.
View details →Valtrex
Valacyclovir is a prodrug of acyclovir and is generally acceptable for FAA certification. Same considerations as acyclovir — the underlying condition matters more than the medication.
View details →Carafate
Sucralfate is generally acceptable for FAA certification. Used for gastric/duodenal ulcer protection, it acts locally in the GI tract with minimal systemic absorption. Report the underlying condition.
View details →Uloric
Febuxostat for gout prevention is generally compatible with FAA certification. Same pathway as allopurinol. Report on your application and ensure gout is well-controlled.
View details →Fosamax
Alendronate for osteoporosis is generally compatible with FAA certification. The medication has no CNS effects and is not on the DNI list. Report on your application and note any GI side effects.
View details →Evista
Raloxifene for osteoporosis prevention is generally compatible with FAA certification. No significant CNS effects. The DVT risk should be discussed with your AME, but the medication itself is not on the DNI list.
View details →Celebrex
Celecoxib is a COX-2 selective NSAID generally acceptable for FAA certification. Like other NSAIDs, the underlying condition being treated is the primary concern. Report on your application.
View details →Mobic
Meloxicam is an NSAID generally acceptable for FAA certification. Same considerations as ibuprofen and naproxen — the underlying condition matters more than the medication itself.
View details →Estrace, Vivelle, Climara
Estradiol hormone replacement therapy is generally acceptable for FAA certification. Report on your application. The underlying condition and any thromboembolic risk should be discussed with your AME.
View details →Linzess
Linaclotide for IBS with constipation is generally compatible with FAA certification. The medication acts locally in the gut with minimal systemic absorption. Report the underlying condition on your application.
View details →Colace
Docusate sodium is an OTC stool softener that is generally acceptable for pilots. No CNS effects, no wait period required. Report on your application if using regularly.
View details →MiraLAX
MiraLAX is an OTC osmotic laxative generally acceptable for pilots. No systemic absorption. Ensure you are not experiencing active GI symptoms while flying.
View details →Various OTC brands
Vitamin D supplementation is generally acceptable for pilots. No aviation safety concerns. Report on your application if prescribed (as opposed to OTC supplement), and note the underlying reason for supplementation.
View details →Lovaza, Vascepa, OTC Fish Oil
Fish oil and omega-3 supplements are generally acceptable for pilots. Prescription-strength versions (Lovaza, Vascepa) for triglyceride management are also acceptable. Report on your application.
View details →Various OTC brands
The FAA's pilot OTC guide lists melatonin as generally safe to fly. No post-dose wait time is specified, but the FAA notes that taking melatonin at the wrong time can worsen jet lag and cause daytime drowsiness. As with any new medication, wait 48 hours after your first dose to confirm you have no side effects before flying.
View details →Voltaren, Cataflam
Diclofenac is an NSAID generally acceptable for FAA certification, whether oral or topical (Voltaren gel). The underlying condition is the primary concern. Topical formulations have minimal systemic absorption.
View details →Monopril
Fosinopril is an ACE inhibitor generally compatible with FAA medical certification. Blood pressure must be well-controlled and the pilot should not experience significant side effects such as dizziness or persistent cough.
View details →Accupril
Quinapril is an ACE inhibitor acceptable for FAA certification when blood pressure is controlled. Same pathway as other ACE inhibitors — report the medication and demonstrate stable blood pressure.
View details →Mavik
Trandolapril is an ACE inhibitor generally compatible with FAA certification. Report the medication and ensure blood pressure is well-controlled with no significant side effects.
View details →Teveten
Eprosartan is an ARB acceptable for FAA medical certification. Like other ARBs, it is not on the Do Not Issue list. Report on your application and demonstrate controlled blood pressure.
View details →Plendil
Felodipine is a dihydropyridine calcium channel blocker generally acceptable for FAA certification. It is a peripheral vasodilator used for hypertension and is not on the Do Not Issue list.
View details →DynaCirc
Isradipine is a calcium channel blocker acceptable for FAA certification when used for hypertension. Report the medication and ensure blood pressure is controlled without significant side effects.
View details →Cardene
Nicardipine is a calcium channel blocker generally compatible with FAA certification for hypertension. It is a peripheral vasodilator and is not on the Do Not Issue list.
View details →Sular
Nisoldipine is a dihydropyridine calcium channel blocker acceptable for FAA certification. Same pathway as other CCBs — report the medication and demonstrate controlled blood pressure.
View details →Trandate
Labetalol is a combined alpha- and beta-blocker generally acceptable for FAA certification when used for hypertension. Report the medication and ensure no exercise intolerance, orthostatic hypotension, or excessive fatigue.
View details →Corgard
Nadolol is a non-selective beta blocker generally acceptable for FAA certification when prescribed for hypertension. If used for cardiac arrhythmia, the underlying condition may require Special Issuance evaluation.
View details →Visken
Pindolol is a beta blocker with intrinsic sympathomimetic activity, generally acceptable for FAA certification when used for hypertension. Less likely to cause bradycardia than other beta blockers.
View details →Sectral
Acebutolol is a cardioselective beta blocker generally acceptable for FAA certification when used for hypertension. If prescribed for ventricular arrhythmias, the underlying condition may require Special Issuance evaluation.
View details →Cytomel
Liothyronine (T3) for hypothyroidism is generally compatible with FAA certification when thyroid levels are stable. Less commonly used than levothyroxine, but follows the same pathway. Stable TSH and free T3/T4 levels are required.
View details →Atrovent
Ipratropium inhalers are generally acceptable for FAA certification. Used for COPD and sometimes asthma, the medication has minimal systemic effects. Pulmonary function testing must meet FAA standards.
View details →Dexilant
Dexlansoprazole is a PPI acceptable for FAA certification. Same pathway as other PPIs — report the medication and ensure the underlying GI condition is well-managed.
View details →Relafen
Nabumetone is a prescription NSAID generally acceptable for FAA certification. It is a prodrug with lower GI toxicity than some NSAIDs. The underlying condition being treated is the primary concern.
View details →Feldene
Piroxicam is a prescription NSAID generally acceptable for FAA certification. It has a long half-life allowing once-daily dosing. Same pathway as other NSAIDs — underlying condition is the primary consideration.
View details →Avodart
Dutasteride is generally acceptable for FAA certification when used for BPH. Same pathway as finasteride — no CNS effects and not on the DNI list. Report on your application.
View details →Rapaflo
Silodosin is a highly selective alpha blocker for BPH generally acceptable for FAA certification. Very uroselective with minimal blood pressure effects. Report on your application.
View details →Uroxatral
Alfuzosin is an alpha blocker for BPH generally compatible with FAA certification. It is uroselective and less likely to cause systemic hypotension than older alpha blockers. Report the medication on your application.
View details →Hytrin
Terazosin is an alpha blocker acceptable for FAA certification for BPH or hypertension. It can cause orthostatic hypotension and a ground trial is recommended before flying.
View details →Zepbound
As of the FAA's August 26, 2026 weight loss medication update, tirzepatide (Zepbound) is acceptable for weight loss when certification criteria are met: an A1C of 6.4% or less, no diagnosis of diabetes, and no history of hypoglycemia requiring intervention. Do not fly for one week after starting, or for 48 hours after any dose increase or formulation change. If you have prediabetes, your AME can issue using the CACI Prediabetes Worksheet. If you take tirzepatide for diabetes (Mounjaro), the diabetes Special Issuance pathway applies instead.
View details →Alli, Xenical
The FAA lists orlistat (Alli, Xenical) as an acceptable weight loss medication when certification criteria are met. Do not fly for 48 hours after first starting it. It can be combined with one diabetic medication used for weight loss, such as metformin or a GLP-1 agonist, under the FAA's weight loss criteria.
View details →Chantix
Varenicline (Chantix) is an acceptable smoking cessation medication. Your AME can issue if you have no history of psychiatric conditions or concerns, and will annotate its use on your exam. Do not fly for one week after starting. No wait is required after each dose. If it is used as part of treatment for a psychiatric condition, the FAA's anxiety and depression guidance applies instead.
View details →Nicorette, NicoDerm CQ, Nicotrol
The FAA lists nicotine replacement as an acceptable smoking cessation medication. Gum, lozenges, and patches need no ground trial and no wait after each dose. Nicotine nasal spray requires a 48-hour ground trial when you first start it.
View details →Levitra, Staxyn
The FAA's ED/BPH guidance lists vardenafil (Levitra, Staxyn) with a required 8-hour wait after the last dose before resuming pilot duties. It is not disqualifying when used for erectile dysfunction or benign prostatic hyperplasia without side effects, as long as the underlying condition isn't aeromedically significant. If you use it for any other condition, the AME must defer. Nitrates are not allowed.
View details →Stendra
The FAA's ED/BPH guidance lists avanafil (Stendra) with a required 8-hour wait after the last dose before resuming pilot duties. It is not disqualifying when used for erectile dysfunction or benign prostatic hyperplasia without side effects, as long as the underlying condition isn't aeromedically significant. If you use it for any other condition, the AME must defer. Nitrates are not allowed.
View details →Clarinex
The FAA lists desloratadine (Clarinex) as an acceptable non-sedating antihistamine, alone or in combination products, if you otherwise meet certification criteria. Wait 48 hours after your first dose to confirm you have no side effects; after that, no wait is required after each dose.
View details →Afrin
The FAA lists oxymetazoline nasal spray (Afrin) as an acceptable decongestant. Wait 48 hours after your first use to confirm you have no side effects; after that, no wait is required after each dose. Decongestants can speed up your heart rate, so use caution if you have a heart condition. Don't fly if congestion keeps you from clearing your ears at ground level.
View details →Boniva
The FAA lists oral ibandronate (Boniva) as an acceptable osteoporosis medication when certification criteria are met, with no initial observation period and no wait after each dose. This guidance applies to osteoporosis treatment only; cancer-related use may carry additional requirements.
View details →Actonel
The FAA lists oral risedronate (Actonel) as an acceptable osteoporosis medication when certification criteria are met, with no initial observation period and no wait after each dose. This guidance applies to osteoporosis treatment only; cancer-related use may carry additional requirements.
View details →Prolia
The FAA lists denosumab (Prolia) as an acceptable osteoporosis medication when certification criteria are met. Do not fly for 48 hours after your first dose, and for 4 hours after each later dose. This guidance applies to osteoporosis treatment only; cancer-related use may carry additional requirements.
View details →Repatha
The FAA lists evolocumab (Repatha) as an acceptable cholesterol medication, alone or in any combination product. Like all cholesterol medications, it requires a 48-hour ground trial when you first start it. No wait is required after each dose.
View details →Praluent
The FAA lists alirocumab (Praluent) as an acceptable cholesterol medication, alone or in any combination product. Like all cholesterol medications, it requires a 48-hour ground trial when you first start it. No wait is required after each dose.
View details →Nexletol
The FAA lists bempedoic acid (Nexletol) as an acceptable cholesterol medication, alone or in any combination product. Like all cholesterol medications, it requires a 48-hour ground trial when you first start it. No wait is required after each dose.
View details →These medications may be approved through the FAA's Special Issuance process. Additional documentation, wait periods, or monitoring may be required.
Zyrtec
The FAA classifies cetirizine (Zyrtec) as a sedating second-generation antihistamine. It is conditionally acceptable: you may use it occasionally (1–2 times a week), but daily use is not acceptable, and you must not fly for 48 hours after each dose. Loratadine (Claritin), fexofenadine (Allegra), and desloratadine (Clarinex) are acceptable without a post-dose wait.
View details →Zoloft
Sertraline (Zoloft) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Prozac
Fluoxetine (Prozac) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). It was one of the original four SSRIs the FAA allowed in 2010. The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Celexa
Citalopram (Celexa) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Lexapro
Escitalopram (Lexapro) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Glucophage, Fortamet
Metformin is approved for pilots with Type 2 diabetes under the Special Issuance process. Pilots must demonstrate stable blood glucose control and absence of significant diabetes-related complications.
View details →Glucotrol
Glipizide is conditionally approved for pilots with Type 2 diabetes. Because sulfonylureas can cause hypoglycemia, the FAA requires additional glucose monitoring documentation compared to metformin alone.
View details →Humalog, Lantus, Novolog, Tresiba
Since November 2019, the FAA allows insulin-treated pilots to hold 1st, 2nd, and 3rd class medical certificates through a rigorous Special Issuance protocol. This was a landmark policy change. The process requires extensive documentation and continuous glucose monitoring.
View details →Coumadin, Jantoven
Warfarin may be approved through Special Issuance, depending on the underlying condition requiring anticoagulation. The INR must be stable and within therapeutic range. The underlying condition (DVT, AFib, mechanical valve) drives the certification pathway.
View details →Ambien, Ambien CR
Zolpidem (Ambien) is a Do Not Fly medication with a mandatory 24-hour wait period after each dose. Occasional use is permitted, but daily or nightly use is not allowed for pilots. Pilots may hold a medical certificate while using zolpidem occasionally, but must not fly within 24 hours of taking a dose.
View details →Imitrex
The FAA's migraine medication guidance (updated 08/26/2026) lists sumatriptan (all formulations) as CACI acceptable for migraine relief when used occasionally. You must not fly for 24 hours after each dose. Daily use is not acceptable, and needing multiple relief medications on a recurring basis is considered complicated migraine, which requires the AME to defer.
View details →Januvia
Sitagliptin is a DPP-4 inhibitor on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization.
View details →Actos
Pioglitazone is a thiazolidinedione on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization.
View details →Xalatan
Latanoprost eye drops are on the FAA's list of CACI glaucoma medications, alone or in combination products. Your AME can issue a certificate if you meet the criteria. Bring a current, detailed clinical progress note from your eye doctor, from a visit no more than 90 days before your exam, covering your history, medications and side effects, exam findings, test results, diagnosis, and plan.
View details →Timoptic
Timolol eye drops are on the FAA's list of CACI glaucoma medications, alone or in combination products. Your AME can issue a certificate if you meet the criteria. Bring a current, detailed clinical progress note from your eye doctor, from a visit no more than 90 days before your exam, covering your history, medications and side effects, exam findings, test results, diagnosis, and plan.
View details →ProAir, Ventolin, Proventil
Albuterol, an inhaled short-acting beta agonist, is on the FAA's list of acceptable medications for asthma under the CACI Asthma Worksheet. Whether your AME can issue depends on how well your asthma is controlled, not the inhaler alone. The worksheet limits rescue inhaler use to no more than 2 times per week. If your only treatment is albuterol as needed on one or two days a week, you don't need spirometry.
View details →Flovent, ArmonAir
Inhaled corticosteroids such as fluticasone are on the FAA's list of acceptable medications for asthma under the CACI Asthma Worksheet. Your AME can issue at the exam if your asthma meets every worksheet criterion, including a breathing test (spirometry) from the last 90 days with FEV1 and FVC at or above 80% of predicted. If you don't meet every item, the FAA decides.
View details →Jardiance
Empagliflozin is an SGLT2 inhibitor that may be approved for pilots with Type 2 diabetes through the Special Issuance process. While it has cardiovascular benefits, the FAA requires documentation of stable glucose control and absence of diabetic ketoacidosis risk.
View details →Victoza, Saxenda
Liraglutide is a GLP-1 receptor agonist that may be approved through the FAA diabetes Special Issuance pathway. Low hypoglycemia risk as monotherapy. When branded as Saxenda for weight loss, the indication may affect the pathway.
View details →Trulicity
Dulaglutide is a weekly GLP-1 agonist that may be approved through the FAA diabetes Special Issuance process. Same pathway as other diabetes medications — stable glucose control and appropriate monitoring required.
View details →Invokana
Canagliflozin is an SGLT2 inhibitor available through the FAA diabetes Special Issuance pathway. Like empagliflozin, documentation must confirm no DKA risk and stable glucose control.
View details →Farxiga
Dapagliflozin is an SGLT2 inhibitor that may be approved through the FAA diabetes Special Issuance process. Standard diabetes pathway requirements apply — stable glucose, A1C monitoring, and no DKA episodes.
View details →Eliquis
Apixaban may be approved through Special Issuance depending on the underlying condition requiring anticoagulation (atrial fibrillation, DVT/PE). The medication itself is increasingly accepted as an alternative to warfarin, but the underlying condition drives the pathway.
View details →Xarelto
Rivaroxaban may be approved through Special Issuance depending on the underlying indication. Like apixaban, the DOAC itself is not specifically prohibited, but the condition requiring anticoagulation must be certifiable.
View details →Pradaxa
Dabigatran may be approved through Special Issuance depending on the underlying condition. Same pathway as other DOACs — the anticoagulant is not specifically prohibited, but the condition requiring it must be certifiable.
View details →Cordarone, Pacerone
Amiodarone requires Special Issuance evaluation. The underlying arrhythmia is the primary concern, and amiodarone's significant side effect profile (thyroid, pulmonary, liver, neurological) requires extensive monitoring. Certification is possible but complex.
View details →Tambocor
Flecainide requires Special Issuance evaluation. Used for atrial fibrillation and supraventricular tachycardia, the underlying arrhythmia and the medication's proarrhythmic potential both require thorough cardiac evaluation.
View details →Betapace, Sorine
Sotalol requires Special Issuance evaluation due to its antiarrhythmic properties and the underlying cardiac condition. It combines beta blocker and class III antiarrhythmic effects, requiring thorough cardiac workup.
View details →Synthroid, Levoxyl
Levothyroxine after thyroidectomy for thyroid cancer requires Special Issuance evaluation. While levothyroxine itself is approved, the cancer history necessitates documentation of remission status, surveillance labs, and endocrinologist follow-up.
View details →Restoril
Temazepam (Restoril) is listed on the FAA sleep aids page with a mandatory 72-hour wait period after each dose. Despite being a benzodiazepine, the FAA permits occasional use for sleep with this extended wait period. Daily or nightly use is not allowed. Note: other benzodiazepines used for anxiety (alprazolam, diazepam, lorazepam, clonazepam) remain fully disqualifying.
View details →Lunesta
Eszopiclone (Lunesta) is a Do Not Fly medication with a mandatory 30-hour wait period after each dose. Occasional use is permitted, but daily or nightly use is not allowed for pilots. The longer wait period compared to zolpidem reflects its longer half-life.
View details →Sonata
Zaleplon (Sonata) is a Do Not Fly medication with a mandatory 12-hour wait period after each dose — the shortest wait of all FAA-listed sleep aids due to its very short half-life. Occasional use is permitted, but daily or nightly use is not allowed for pilots.
View details →Wellbutrin, Zyban
Bupropion's FAA status depends on the formulation and why you take it. Sustained-release (SR) and extended-release (ER/XL) Wellbutrin were added to the FAA's conditionally acceptable antidepressants on May 31, 2023, and are considered case by case through Special Issuance with a HIMS AME evaluation. Immediate-release (IR) bupropion is unacceptable. For smoking cessation (Zyban), the FAA does not issue a medical during a first treatment course and requires a 7-day no-fly after the last dose. Bupropion combined with naltrexone (Contrave) for weight loss is on the Do Not Issue list.
View details →Benadryl
The FAA classifies diphenhydramine (Benadryl) as a sedating first-generation antihistamine. It is conditionally acceptable only for occasional use (1–2 times a week), never daily, and you must not fly for 60 hours after each dose. It is found in many OTC allergy, cold, and sleep products, including most "PM" formulas, and the FAA notes it is the medication most commonly found on autopsy after aircraft accidents.
View details →Tradjenta
Linagliptin is a DPP-4 inhibitor on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization.
View details →Onglyza
Saxagliptin is a DPP-4 inhibitor on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization.
View details →Trexall, Rheumatrex
Methotrexate may be conditionally approved depending on the underlying autoimmune condition. Used for rheumatoid arthritis and psoriasis, the medication requires monitoring but is not specifically on the DNI list. The underlying condition drives the pathway.
View details →Humira
The FAA lists adalimumab (Humira) as an acceptable biologic when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars (such as Hadlima) are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Deltasone, Rayos
Prednisone is conditionally acceptable. Short-term courses (e.g., for asthma exacerbation) may be acceptable after the course is completed and symptoms resolve. Chronic systemic steroid use requires evaluation for side effects including mood changes, glucose elevation, and adrenal suppression.
View details →Zofran
The FAA's migraine medication guidance (updated 08/26/2026) lists ondansetron (Zofran) as CACI acceptable for occasional use for nausea and vomiting associated with migraine, with a 24-hour no-fly period after each dose. Daily use is not acceptable. Do not fly while you are nauseated or ill; for other causes of nausea, the underlying condition determines eligibility.
View details →Reglan
The FAA's migraine medication guidance (updated 08/26/2026) lists metoclopramide as CACI acceptable for nausea and vomiting associated with migraine when used occasionally, with a 36-hour no-fly period after each dose. It is not on the FAA's Do Not Issue or Do Not Fly tables. Do not fly while symptomatic. For other uses, the underlying condition determines eligibility — discuss it with your AME.
View details →Cymbalta
Duloxetine (Cymbalta) is one of the FAA's conditionally acceptable antidepressants under the Antidepressant Protocol (formerly the SSRI Protocol), which added SNRIs on April 24, 2024. The AME cannot issue; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Effexor, Effexor XR
Venlafaxine (Effexor) is one of the FAA's conditionally acceptable antidepressants under the Antidepressant Protocol (formerly the SSRI Protocol), which added SNRIs on April 24, 2024. The AME cannot issue; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Spiriva
Tiotropium may be conditionally approved depending on the severity of the underlying COPD or asthma. Mild, well-controlled cases with adequate pulmonary function may qualify. Severe COPD is generally disqualifying.
View details →Pulmicort
Budesonide is an inhaled corticosteroid, a medication class the FAA lists as acceptable for asthma on the CACI Asthma Worksheet. Your AME can issue at the exam if your asthma meets every worksheet criterion, including spirometry from the last 90 days with FEV1 and FVC at or above 80% of predicted. If you don't meet every item, the FAA decides.
View details →Foradil, Perforomist
Formoterol is an inhaled long-acting beta agonist, a medication class the FAA lists as acceptable for asthma on the CACI Asthma Worksheet. For asthma, your AME can issue if you meet every worksheet criterion. For COPD, emphysema, or chronic bronchitis, the FAA's disposition table tells the AME to defer and send your records to the FAA for a possible Special Issuance.
View details →Serevent
Salmeterol is an inhaled long-acting beta agonist, a medication class the FAA lists as acceptable for asthma on the CACI Asthma Worksheet. For asthma, your AME can issue if you meet every worksheet criterion. For COPD, emphysema, or chronic bronchitis, the FAA's disposition table tells the AME to defer and send your records to the FAA for a possible Special Issuance.
View details →Maxalt
The FAA's migraine medication guidance (updated 08/26/2026) lists rizatriptan as CACI acceptable for migraine relief when used occasionally. You must not fly for 24 hours after each dose. Daily use is not acceptable, and needing multiple relief medications on a recurring basis is considered complicated migraine, which requires the AME to defer.
View details →Lanoxin
Digoxin requires Special Issuance evaluation. Used for heart failure and atrial fibrillation, both the medication and underlying cardiac condition require thorough evaluation. Narrow therapeutic index makes monitoring critical.
View details →Multaq
Dronedarone requires Special Issuance evaluation. Used for atrial fibrillation, the underlying arrhythmia and medication both require comprehensive cardiac workup for FAA certification.
View details →Rhythmol
Propafenone requires Special Issuance evaluation. Used for atrial fibrillation and supraventricular tachycardia, the medication and underlying arrhythmia require comprehensive cardiac documentation.
View details →Ozempic, Rybelsus
Semaglutide for Type 2 diabetes (Ozempic/Rybelsus) may be approved through the FAA diabetes Special Issuance pathway. This is distinct from the weight loss indication (Wegovy). Standard diabetes monitoring and documentation requirements apply.
View details →AndroGel, Testim, Depo-Testosterone
Testosterone replacement therapy may be conditionally acceptable for FAA certification. Testosterone levels must be within normal physiologic range and the underlying hypogonadism must be documented. Supraphysiologic dosing is not acceptable.
View details →Phenergan
The FAA's migraine medication guidance (updated 08/26/2026) lists promethazine as CACI acceptable for nausea and vomiting associated with migraine when used occasionally, with a 96-hour no-fly period after each dose. It is not on the FAA's Do Not Issue or Do Not Fly tables. Do not fly while symptomatic. For other uses, the underlying condition determines eligibility — discuss it with your AME.
View details →DDAVP, Stimate
Desmopressin may be conditionally approved depending on the underlying condition (diabetes insipidus, bedwetting, von Willebrand disease). The condition and electrolyte stability determine the certification pathway.
View details →Plaquenil
Hydroxychloroquine may be conditionally approved depending on the underlying autoimmune condition. The main aviation concern is retinal toxicity with long-term use, which can affect visual fields. Regular ophthalmologic screening is required.
View details →Arava
Leflunomide may be conditionally approved depending on the underlying rheumatoid arthritis severity and medication side effects. Not on the DNI list, but the underlying condition and immunosuppression require evaluation.
View details →Azulfidine
Sulfasalazine may be conditionally approved depending on whether used for rheumatoid arthritis or inflammatory bowel disease. The medication itself is not on the DNI list, but the underlying condition drives the certification pathway.
View details →Asacol, Lialda, Pentasa
Mesalamine for ulcerative colitis or Crohn's disease may be conditionally approved. The medication itself is not on the DNI list, but the underlying IBD severity and symptom control determine the certification pathway.
View details →Imuran, Azasan
Azathioprine may be conditionally approved depending on the underlying autoimmune condition. As an immunosuppressant, infection risk and the underlying disease activity must be well-documented for certification.
View details →Prograf
Tacrolimus for organ transplant recipients may be considered through Special Issuance, though the pathway is complex. Organ transplant certification is one of the most challenging Special Issuance categories, requiring extensive documentation of graft function and overall health.
View details →CellCept, Myfortic
Mycophenolate may be conditionally approved through Special Issuance depending on whether used for transplant or autoimmune disease. Same extensive evaluation pathway as other immunosuppressants.
View details →Corlanor
Ivabradine requires Special Issuance evaluation. Used for heart failure with reduced ejection fraction, the underlying cardiac condition is the primary concern. Comprehensive cardiac documentation required.
View details →Entresto
Sacubitril-valsartan requires Special Issuance evaluation. As a heart failure medication, the underlying cardiac condition must be thoroughly documented including ejection fraction, functional status, and exercise tolerance.
View details →Savaysa
Edoxaban may be approved through Special Issuance depending on the underlying condition requiring anticoagulation. Like other DOACs, the medication itself is not specifically prohibited, but the underlying condition must be certifiable.
View details →Tikosyn
Dofetilide requires Special Issuance evaluation. Used for atrial fibrillation and atrial flutter, the underlying arrhythmia and the medication's QT-prolonging potential both require thorough cardiac evaluation and monitoring.
View details →Nesina
Alogliptin is a DPP-4 inhibitor on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization.
View details →Accolate
Zafirlukast is a leukotriene receptor antagonist, a medication class the FAA lists as acceptable for asthma on the CACI Asthma Worksheet. Your AME can issue at the exam if your asthma meets every worksheet criterion, including spirometry from the last 90 days with FEV1 and FVC at or above 80% of predicted. If you don't meet every item, the FAA decides.
View details →Theo-24, Elixophyllin
Theophylline has a narrow therapeutic index and can cause significant side effects at supratherapeutic levels. The FAA may require documentation of stable therapeutic levels and absence of CNS side effects such as tremor, insomnia, or seizures.
View details →Toradol
The FAA's migraine medication guidance (updated 08/26/2026) lists ketorolac, by all routes of administration, as SI Conditional. It is intended for short-term use (less than 5 days) for severe or intractable headaches, not mild symptoms, and requires a 36-hour no-fly period after each dose. Do not fly while in acute pain, and report any use to your AME.
View details →Accutane, Claravis, Absorica
You cannot fly while taking oral isotretinoin. The FAA requires that it be permanently discontinued for at least 2 weeks, confirmed by the prescribing physician, before you can be considered, because it can cause decreased night vision and depression — effects that can occur even after stopping. You will also need an eye evaluation and a signed statement confirming no visual or psychiatric symptoms and acknowledging that you must get FAA clearance before flying if you resume it. Topical acne medications and oral antibiotics such as tetracycline are acceptable.
View details →Alphagan, Alphagan P
Brimonidine eye drops are on the FAA's list of CACI glaucoma medications, alone or in combination products. Your AME can issue a certificate if you meet the criteria. Bring a current, detailed clinical progress note from your eye doctor, from a visit no more than 90 days before your exam, covering your history, medications and side effects, exam findings, test results, diagnosis, and plan.
View details →Trusopt
Dorzolamide eye drops are on the FAA's list of CACI glaucoma medications, alone or in combination products. Your AME can issue a certificate if you meet the criteria. Bring a current, detailed clinical progress note from your eye doctor, from a visit no more than 90 days before your exam, covering your history, medications and side effects, exam findings, test results, diagnosis, and plan.
View details →Mounjaro
Tirzepatide (Mounjaro) is on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. After approval, an AME may issue subsequent certificates under the terms of the Authorization. If you take tirzepatide for weight loss without a diabetes diagnosis (Zepbound), a different FAA pathway applies.
View details →Amaryl
Glimepiride (Amaryl) is a sulfonylurea on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. Sulfonylureas carry the FAA's longest non-insulin observation period: 60 days after starting.
View details →Diabeta
Glyburide (Diabeta) is a sulfonylurea on the FAA's list of acceptable diabetes medications, but diabetes treated with any medication requires an Authorization for Special Issuance. The FAA makes the initial decision and the AME must defer. Sulfonylureas carry the FAA's longest non-insulin observation period: 60 days after starting.
View details →Pristiq
Desvenlafaxine (Pristiq) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). It was added when the FAA expanded the protocol to SNRIs on April 24, 2024. The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Viibryd
Vilazodone (Viibryd) is one of nine conditionally acceptable antidepressants under the FAA's Antidepressant Protocol (formerly the SSRI Protocol). The AME cannot issue your first certificate; the FAA decides case by case through Special Issuance. You must be stable on the same dose for at least 3 continuous months without aeromedically significant side effects, take it as your only antidepressant, and be evaluated by a HIMS AME.
View details →Rozerem
Ramelteon (Rozerem) is listed on the FAA's sleep aids page with a required 24-hour wait after each dose before resuming pilot duties. Occasional or limited use of sleep aids is allowed, but daily or nightly use is not allowed for any reason. Conditions that chronically interfere with sleep are disqualifying on their own.
View details →Nurtec ODT
The FAA's migraine medication guidance (updated 08/26/2026) lists rimegepant (Nurtec ODT) as CACI acceptable for migraine relief when used occasionally. You must not fly for 24 hours after each dose. Daily use is not acceptable, and needing multiple relief medications on a recurring basis is considered complicated migraine, which requires the AME to defer.
View details →Ubrelvy
The FAA's migraine medication guidance (updated 08/26/2026) lists ubrogepant (Ubrelvy) as CACI acceptable for migraine relief when used occasionally. You must not fly for 24 hours after each dose. Daily use is not acceptable, and needing multiple relief medications on a recurring basis is considered complicated migraine, which requires the AME to defer.
View details →Relpax
The FAA's migraine medication guidance (updated 08/26/2026) lists eletriptan (Relpax) as CACI acceptable for migraine relief when used occasionally. You must not fly for 48 hours after each dose. Daily use is not acceptable, and needing multiple relief medications on a recurring basis is considered complicated migraine, which requires the AME to defer.
View details →Qulipta
The FAA's migraine medication guidance lists atogepant (Qulipta) as CACI acceptable for migraine prevention. You must complete a 7-day ground trial to confirm it works and causes no adverse effects before flying. No wait is required after each dose.
View details →Aimovig
The FAA's migraine medication guidance lists erenumab (Aimovig) as CACI acceptable for migraine prevention. You must complete a 7-day ground trial to confirm it works and causes no adverse effects before flying. No wait is required after each dose.
View details →Ajovy
The FAA's migraine medication guidance lists fremanezumab (Ajovy) as CACI acceptable for migraine prevention. You must complete a 7-day ground trial to confirm it works and causes no adverse effects before flying. No wait is required after each dose.
View details →Emgality
The FAA's migraine medication guidance lists galcanezumab (Emgality) as CACI acceptable for migraine prevention. You must complete a 7-day ground trial to confirm it works and causes no adverse effects before flying. No wait is required after each dose.
View details →Reyvow
The FAA's migraine medication guidance lists lasmiditan (Reyvow) as SI Conditional for migraine relief, with a 48-hour no-fly period after each dose. It is unacceptable for migraine prevention. Discuss your migraine history and treatment with your AME before flying.
View details →Botox
The FAA's migraine medication guidance lists botulinum toxin (Botox) for migraine prevention as SI Conditional. It is reserved for severe, refractory headaches and may cause delayed side effects such as muscle weakness, excessive fatigue, or eye symptoms. You must complete a 1-month ground trial and not fly for 72 hours after each treatment.
View details →Xyzal
The FAA classifies levocetirizine (Xyzal) as a sedating second-generation antihistamine. It is conditionally acceptable: you may use it occasionally (1–2 times a week), but daily use is not acceptable, and you must not fly for 48 hours after each dose. Loratadine (Claritin), fexofenadine (Allegra), and desloratadine (Clarinex) are acceptable without a post-dose wait.
View details →Chlor-Trimeton, Coricidin
The FAA classifies chlorpheniramine as a sedating first-generation antihistamine. It is conditionally acceptable only for occasional use (1–2 times a week), never daily, and you must not fly for 5 days after each dose because of its long half-life. It is common in cold and allergy combination products — including Coricidin HBP — so check labels carefully.
View details →Unisom SleepTabs, NyQuil
The FAA classifies doxylamine as a sedating first-generation antihistamine. It is conditionally acceptable only for occasional use (1–2 times a week), never daily, and you must not fly for 60 hours after each dose. It is the active ingredient in many OTC sleep aids and nighttime cold medicines, including Unisom SleepTabs and NyQuil.
View details →Enbrel
The FAA lists etanercept (Enbrel) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Remicade, Inflectra, Renflexis
The FAA lists infliximab (Remicade, Inflectra, Renflexis) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 24 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Stelara
The FAA lists ustekinumab (Stelara) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Cosentyx
The FAA lists secukinumab (Cosentyx) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Skyrizi
The FAA lists risankizumab (Skyrizi) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Dupixent
The FAA lists dupilumab (Dupixent) as a conditionally acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and not fly for 4 hours after each dose. FDA-approved biosimilars are also acceptable, and switching between biologics for the same condition requires a 48-hour ground trial.
View details →Xeljanz
The FAA lists tofacitinib (Xeljanz) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and no wait is required after each dose. The FAA lists it among non-biologic medications in its biologics guidance.
View details →Rinvoq
The FAA lists upadacitinib (Rinvoq) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and no wait is required after each dose. The FAA lists it among non-biologic medications in its biologics guidance.
View details →Otezla
The FAA lists apremilast (Otezla) as an acceptable medication when used alone, as long as the underlying condition qualifies for certification — your diagnosis is what determines eligibility. You must complete a 2-week ground trial when starting and no wait is required after each dose. The FAA lists it among non-biologic medications in its biologics guidance.
View details →Paxlovid
The FAA accepts FDA-approved COVID-19 treatments such as Paxlovid, but you cannot fly while taking them or while you are symptomatic or infected. Before returning to flying, you must wait 24 hours after your last dose, be free of significant side effects, meet current CDC and FAA recovery guidelines, and meet the FAA's COVID-19 disposition requirements.
View details →These medications are on the FAA's Do Not Issue or Do Not Fly lists. A washout period and evaluation are typically required after discontinuation.
Adderall, Adderall XR
Adderall (amphetamine/dextroamphetamine) is an ADHD medication on the FAA's Do Not Issue list. If you currently take it, including as needed, the AME must defer. If your prescriber says you can safely stop, you must be off it at least 90 days before Standard Track testing by an FAA HIMS neuropsychologist. Any ADHD medication use in the past 4 years rules out the Fast Track.
View details →Ritalin, Concerta, Focalin
Methylphenidate (Ritalin, Concerta, Focalin) is an ADHD medication on the FAA's Do Not Issue list. If you currently take it, including as needed, the AME must defer. Once stopped, you must be off it at least 90 days before Standard Track testing. Any use in the past 4 years means the Standard Track; the Fast Track is only for people with no ADHD medication, symptoms, or instability in 4 years.
View details →Xanax
The FAA's Do Not Fly table lists alprazolam (Xanax) among anti-anxiety medications that can impair performance even when you feel alert. If you use it routinely, the AME must defer, and an ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose. The underlying anxiety condition is evaluated separately.
View details →Valium
Diazepam (Valium) is a benzodiazepine. The FAA's Do Not Fly table covers anti-anxiety medications ("including but not limited to" alprazolam and lorazepam), which can impair performance even when you feel alert. If you use it routinely, the AME must defer, and an ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose — diazepam's long half-life makes that wait especially long.
View details →Ultram, ConZip
The FAA's Do Not Fly table allows tramadol (Ultram) to be used occasionally for a time-limited condition, such as recovery from surgery or dental work, but you must not fly while taking it or until the no-fly time has passed after your last dose (at least 5 times its maximum half-life). An ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list, and the underlying pain condition is evaluated separately.
View details →Neurontin, Gralise
Gabapentin is on the FAA's Do Not Issue list due to its CNS effects. It is disqualifying regardless of whether it is prescribed for seizures, neuropathic pain, or off-label uses like anxiety.
View details →Medical marijuana, THC products, CBD with THC
Marijuana in all forms, including medical marijuana that is legal under your state's law, is disqualifying for FAA medical certification. A federal order effective April 28, 2026 moved only marijuana in FDA-approved drugs and state-licensed medical marijuana to Schedule III; all other marijuana remains Schedule I, and full rescheduling is not final. The FAA's policy has not changed: its Do Not Issue list covers controlled substances in Schedules I through V, including medical marijuana. CBD itself is not specifically disqualifying, but a marijuana-positive DOT drug test caused by a CBD product is treated as positive.
View details →Provigil
Modafinil is on the FAA's Do Not Issue list. It is disqualifying regardless of indication — whether prescribed for narcolepsy, shift work disorder, or off-label ADHD use. The underlying sleep disorder also requires evaluation.
View details →Vicodin, Norco, Lortab
The FAA's Do Not Fly table allows hydrocodone (Vicodin, Norco) to be used occasionally for a time-limited condition, such as recovery from surgery or dental work, but you must not fly while taking it or until the no-fly time has passed after your last dose (at least 5 times its maximum half-life). An ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list, and the underlying pain condition is evaluated separately.
View details →Robaxin
The FAA's Do Not Fly table lists muscle relaxants as a class ("including but not limited to" carisoprodol and cyclobenzaprine) because they can impair performance even when you feel alert. Methocarbamol (Robaxin) is not named individually but belongs to this class. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose. If you use it routinely, the AME must defer.
View details →Lamictal
Lamotrigine is not acceptable for FAA medical certification. The FAA's Do Not Issue table covers seizure medications even when used for non-seizure conditions, and mood stabilizers are also on the list. The FAA's migraine guidance lists lamotrigine as unacceptable for migraine prevention. An AME cannot issue while you are taking it; clearance from the FAA is required.
View details →Ativan
The FAA's Do Not Fly table lists lorazepam (Ativan) among anti-anxiety medications that can impair performance even when you feel alert. If you use it routinely, the AME must defer, and an ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose. The underlying anxiety condition is evaluated separately.
View details →Klonopin
Clonazepam (Klonopin) is not acceptable for FAA medical certification while you are taking it on an ongoing basis. It is both an anti-anxiety medication and a seizure medication, and the FAA's Do Not Issue table covers seizure medications even when they are used for non-seizure conditions, as well as any ongoing prescription for chronic use of a controlled substance. The underlying anxiety or seizure condition also requires FAA evaluation.
View details →OxyContin, Percocet, Roxicodone
The FAA's Do Not Fly table allows oxycodone (OxyContin, Percocet) to be used occasionally for a time-limited condition, such as recovery from surgery or dental work, but you must not fly while taking it or until the no-fly time has passed after your last dose (at least 5 times its maximum half-life). An ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list, and the underlying pain condition is evaluated separately.
View details →MS Contin, Kadian
The FAA's Do Not Fly table allows morphine to be used occasionally for a time-limited condition, such as recovery from surgery or dental work, but you must not fly while taking it or until the no-fly time has passed after your last dose (at least 5 times its maximum half-life). An ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list, and the underlying pain condition is evaluated separately.
View details →Tylenol with Codeine
The FAA's Do Not Fly table allows codeine to be used occasionally for a time-limited condition, such as recovery from surgery or dental work, but you must not fly while taking it or until the no-fly time has passed after your last dose (at least 5 times its maximum half-life). An ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list, and the underlying pain condition is evaluated separately.
View details →Duragesic, Actiq, Subsys
Fentanyl (patches, lozenges, and other forms) is a potent narcotic and a controlled substance. Patches and other long-acting forms are used for ongoing pain, and the FAA's Do Not Issue table covers any ongoing prescription for chronic use of a controlled substance. Narcotic pain relievers are also on the Do Not Fly table, so do not fly while using fentanyl or until the no-fly time has passed after your last dose. The underlying pain condition is evaluated separately.
View details →Suboxone, Subutex, Sublocade
Buprenorphine (Suboxone, Subutex, Sublocade) is a controlled substance usually taken on an ongoing basis for opioid use disorder or chronic pain. The FAA's Do Not Issue table covers any ongoing prescription for chronic use of a controlled substance, so an AME cannot issue while you are taking it. Opioid use disorder also requires its own FAA review, which runs through a HIMS AME.
View details →Belsomra
Suvorexant is on the FAA's DNI list. As a dual orexin receptor antagonist used for insomnia, it is disqualifying due to its sedating mechanism of action.
View details →Seroquel
Quetiapine is on the FAA's DNI list. All antipsychotic medications are disqualifying. Even low-dose quetiapine prescribed off-label for sleep is disqualifying. The underlying condition also requires evaluation.
View details →Zyprexa
Olanzapine is on the FAA's DNI list. All antipsychotic medications are disqualifying regardless of indication. The underlying psychiatric condition also requires evaluation.
View details →Risperdal
Risperidone is on the FAA's DNI list. All antipsychotic medications are disqualifying for aviation certification due to sedation, cognitive effects, and the underlying conditions they treat.
View details →Abilify
Aripiprazole is on the FAA's DNI list. Despite being considered less sedating than other antipsychotics, all medications in this class are disqualifying. Even when used as augmentation for depression, it remains disqualifying.
View details →Lithobid, Eskalith
Lithium is on the FAA's DNI list. As a mood stabilizer for bipolar disorder, both the medication and the underlying condition are disqualifying. Lithium's narrow therapeutic index and potential for toxicity make it incompatible with aviation.
View details →Depakote, Depakene
Valproic acid is on the FAA's DNI list. Whether prescribed for seizures, bipolar disorder, or migraine prevention, it is disqualifying. The underlying conditions it treats are also typically disqualifying.
View details →Tegretol, Carbatrol
Carbamazepine is on the FAA's DNI list. Used for seizures, bipolar disorder, and trigeminal neuralgia, it is disqualifying regardless of indication. Both the medication and underlying conditions are problematic for certification.
View details →Vyvanse
Lisdexamfetamine (Vyvanse) is an ADHD medication on the FAA's Do Not Issue list. If you currently take it, the AME must defer. After stopping, you must be off it at least 90 days before Standard Track testing by an FAA HIMS neuropsychologist. If you haven't taken any ADHD medication in 4 years and meet the other Fast Track criteria, your AME may be able to issue.
View details →Strattera
Atomoxetine (Strattera) is a non-stimulant, but the FAA's Do Not Issue list covers all ADHD medications, so current use is not acceptable. You must be off it at least 90 days before Standard Track testing. Use in the past 4 years puts you on the Standard Track; the Fast Track requires 4 years without any ADHD medication.
View details →BuSpar
Buspirone is on the FAA's DNI list. Although it is a non-benzodiazepine anxiolytic with less sedation risk, it is still disqualifying for aviation. The underlying anxiety disorder also requires evaluation.
View details →Flexeril, Amrix
The FAA's Do Not Fly table names cyclobenzaprine (Flexeril) among muscle relaxants that can impair performance even when you feel alert. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose. If you use it routinely, the AME must defer.
View details →Soma
The FAA's Do Not Fly table names carisoprodol (Soma) among muscle relaxants that can impair performance even when you feel alert. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose. If you use it routinely, the AME must defer.
View details →Zanaflex
Tizanidine is on the FAA's DNI list. As a centrally-acting muscle relaxant, it causes sedation and hypotension that are incompatible with safe flight operations.
View details →Lioresal, Gablofen
Baclofen is on the FAA's DNI list. It is a centrally-acting muscle relaxant with sedating effects that are disqualifying for aviation. The underlying spasticity condition may also affect certification.
View details →Topamax, Qudexy
Topiramate is on the FAA's DNI list. Whether prescribed for migraine prevention, seizures, or weight loss, it is disqualifying due to cognitive side effects ('brain fog') and its anticonvulsant classification.
View details →Adipex-P, Lomaira
Phentermine is on the FAA's DNI list. As a sympathomimetic amine chemically related to amphetamine, it is disqualifying. It can cause cardiovascular effects, insomnia, and CNS stimulation incompatible with aviation safety.
View details →Lyrica
Pregabalin is on the FAA's DNI list. Like gabapentin, it has significant CNS effects including dizziness, somnolence, and cognitive impairment. It is disqualifying regardless of indication.
View details →Desyrel
Trazodone (Desyrel) is not acceptable for FAA medical certification. The FAA's Do Not Issue table covers psychiatric medications, including antidepressants, even when they are used for other conditions such as insomnia, and trazodone is not on the FAA's list of conditionally acceptable antidepressants. An AME cannot issue while you are taking it.
View details →Remeron
Mirtazapine (Remeron) is not acceptable for FAA medical certification. The FAA's Do Not Issue table covers psychiatric medications, including antidepressants, even when they are used for other conditions such as insomnia, and mirtazapine is not on the FAA's list of conditionally acceptable antidepressants. An AME cannot issue while you are taking it.
View details →Elavil
Amitriptyline is on the FAA's DNI list. All tricyclic antidepressants are disqualifying due to their sedating, anticholinergic, and cardiac effects. Even low doses for migraine or neuropathy are disqualifying.
View details →Pamelor
Nortriptyline is on the FAA's DNI list. Like all tricyclic antidepressants, it is disqualifying regardless of indication (depression, neuropathic pain, migraine prevention).
View details →Vistaril, Atarax
Hydroxyzine is disqualifying for FAA certification. As a first-generation antihistamine with significant sedating properties, it is used for anxiety and insomnia. Both the sedation and the underlying anxiety condition require evaluation.
View details →Catapres, Kapvay
Clonidine is on the FAA's DNI list. As a centrally-acting antihypertensive, it causes significant sedation, drowsiness, and cognitive effects. Whether prescribed for hypertension or ADHD, it is disqualifying.
View details →Keppra
Levetiracetam is on the FAA's DNI list. All anticonvulsant medications are disqualifying. The underlying seizure disorder is also independently disqualifying for FAA certification.
View details →Dilantin
Phenytoin is on the FAA's DNI list. All anticonvulsant medications are disqualifying. The underlying seizure disorder is independently disqualifying.
View details →Trileptal
Oxcarbazepine is on the FAA's DNI list. Like all anticonvulsants, it is disqualifying regardless of indication (seizures, bipolar disorder, neuropathic pain).
View details →Paxil, Pexeva
Paroxetine (Paxil) is an SSRI, but the FAA's Antidepressant Medications table lists it as unacceptable, alone or in any combination product, so it cannot be used under the Antidepressant Protocol. Nine other antidepressants are conditionally acceptable. Never stop or switch medication on your own — talk with your psychiatrist and a HIMS AME, and expect to need 3 months of stability on any new medication.
View details →Luvox
Fluvoxamine (Luvox) is an SSRI, but the FAA's Antidepressant Medications table lists it as unacceptable, alone or in any combination product, so it cannot be used under the Antidepressant Protocol. Nine other antidepressants are conditionally acceptable. Never stop or switch medication on your own — talk with your psychiatrist and a HIMS AME, and expect to need 3 months of stability on any new medication.
View details →Dexedrine, Zenzedi
Dextroamphetamine (Dexedrine, Zenzedi) is a stimulant ADHD medication on the FAA's Do Not Issue list. If you currently take it, the AME must defer. After stopping, you must be off it at least 90 days before Standard Track testing. Any ADHD medication use in the past 4 years rules out the Fast Track.
View details →Intuniv, Tenex
Guanfacine is Do Not Issue for any use. The FAA's antihypertensive guidance lists guanfacine (Tenex) as an unacceptable blood pressure medication, and ADHD medications (Intuniv) are on the Do Not Issue list. If it was prescribed for ADHD, you must be off it at least 90 days before Standard Track testing, and use in the past 4 years rules out the ADHD Fast Track.
View details →Lyrica
Pregabalin prescribed for fibromyalgia is still on the FAA's DNI list. The indication does not change its disqualifying status. Fibromyalgia itself may also require evaluation depending on severity.
View details →Ditropan
Oxybutynin is on the FAA's Do Not Issue list. The FAA names it among overactive bladder medications that carry strong warnings about sedation and impaired cognition. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. The FAA's pilot OTC guide also lists the over-the-counter patch (Oxytrol) as a NO GO medication.
View details →Vesicare
Solifenacin is on the FAA's Do Not Issue list. The FAA names it, along with oxybutynin and tolterodine, among overactive bladder medications that carry strong warnings about sedation and impaired cognition. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required.
View details →Lomotil
Diphenoxylate-atropine (Lomotil) is disqualifying as it contains an opioid derivative. Pilots should use loperamide (Imodium) as an alternative antidiarrheal that is generally acceptable.
View details →Transderm Scop
Scopolamine patches are disqualifying for pilots. Despite being used for motion sickness, scopolamine causes significant anticholinergic effects including blurred vision, drowsiness, and disorientation that are incompatible with aviation.
View details →Antivert, Bonine, Dramamine Less Drowsy
Meclizine is disqualifying for pilots. Although marketed as 'less drowsy,' it is still a first-generation antihistamine with sedating properties. The underlying vertigo or motion sickness also raises flight safety concerns.
View details →Horizant
Gabapentin enacarbil is on the FAA's DNI list, same as gabapentin. Used for restless legs syndrome, both the medication and the sleep-disrupting condition require evaluation. The underlying RLS may affect sleep quality and fitness to fly.
View details →Nitrostat, Nitro-Dur
Nitroglycerin and all nitrate medications are explicitly listed as "not allowed" on the FAA AME Guide antihypertensives page. The use of nitrates indicates underlying coronary artery disease requiring active angina management, which is disqualifying. Pilots with CAD who no longer require nitrates may pursue Special Issuance for the underlying cardiac condition.
View details →Imdur, Monoket
Isosorbide mononitrate and all nitrate medications are explicitly listed as "not allowed" on the FAA AME Guide antihypertensives page. Chronic nitrate use for angina prevention indicates active coronary artery disease management, which is disqualifying. Pilots may pursue Special Issuance for the underlying CAD if nitrates are discontinued.
View details →Ranexa
Ranolazine is on the FAA's Do Not Issue list under angina medications, alongside nitrates. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. The underlying coronary artery disease also requires its own FAA cardiac review.
View details →Bentyl
Dicyclomine is on the FAA's DNI list due to its anticholinergic effects which can cause drowsiness, blurred vision, dizziness, and cognitive impairment. These effects are incompatible with safe flight operations.
View details →Levsin, Anaspaz
Hyoscyamine is on the FAA's DNI list due to anticholinergic effects including blurred vision, drowsiness, dizziness, and cognitive impairment that are incompatible with aviation safety.
View details →Sinequan, Silenor
Doxepin is on the FAA's DNI list. Whether used at antidepressant doses (Sinequan) or low doses for insomnia (Silenor), it is disqualifying. All tricyclic antidepressants are incompatible with aviation.
View details →Detrol, Detrol LA
Tolterodine is on the FAA's DNI list due to anticholinergic effects. Although marketed as having fewer CNS effects than oxybutynin, it still causes blurred vision and drowsiness that are incompatible with aviation safety.
View details →Qsymia
The FAA lists phentermine-topiramate (Qsymia) as an unacceptable weight loss medication, prohibited as a single agent or in any combination product. Sympathomimetic weight loss drugs such as phentermine are also on the FAA's Do Not Issue list. An AME cannot issue while you are taking it.
View details →Contrave
Bupropion-naltrexone (Contrave) is on the FAA's Do Not Issue list and is listed as an unacceptable weight loss medication. An AME cannot issue a medical certificate while you are taking it. Bupropion alone in SR/ER form is handled differently, under the FAA's Antidepressant Protocol.
View details →Symlin
Pramlintide (Symlin) is the one diabetes medication specifically named on the FAA's Do Not Issue list. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. Most other diabetes medications are allowed through Special Issuance.
View details →Trintellix
The FAA's Antidepressant Medications table lists vortioxetine (Trintellix) as unacceptable, alone or in any combination product, so it cannot be used under the Antidepressant Protocol. Nine other antidepressants are conditionally acceptable through Special Issuance. Never stop or switch medication on your own — talk with your psychiatrist and a HIMS AME, and expect to need 3 months of stability on any new medication.
View details →Spravato
The FAA's Antidepressant Medications table lists esketamine (Spravato) as unacceptable, alone or in any combination product, so it cannot be used under the Antidepressant Protocol. Nine other antidepressants are conditionally acceptable through Special Issuance. Never stop or switch medication on your own — talk with your psychiatrist and a HIMS AME, and expect to need 3 months of stability on any new medication.
View details →Halcion
The FAA's Do Not Fly table names triazolam (Halcion) among anti-anxiety medications that can impair performance even when you feel alert. If you use it routinely, the AME must defer, and an ongoing prescription for chronic use of a controlled substance is on the Do Not Issue list. Do not fly while taking it or until at least 5 times its maximum half-life has passed since your last dose.
View details →Fioricet, Fiorinal
The FAA's migraine medication guidance lists butalbital combinations — acetaminophen with butalbital (Fioricet) and aspirin with butalbital (Fiorinal) — as unacceptable, alone or in any combination product. An AME cannot issue while you are using them. Other migraine relief options, such as triptans and gepants, are acceptable for occasional use with specific no-fly times.
View details →Lariam
The FAA considers mefloquine (Lariam) absolutely disqualifying for pilots because it can cause neuropsychiatric side effects even weeks after you stop taking it. It must be discontinued for at least 4 weeks before consideration, you must contact an FAA flight surgeon or your AME before resuming pilot duties, and you must have had no neurologic or psychiatric symptoms during or after use. Most other malaria medications are allowed.
View details →Mirapex
Pramipexole (Mirapex) is on the FAA's Do Not Issue list. Dopamine agonists are disqualifying whether used for Parkinson's disease, restless legs syndrome, or another condition. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. The underlying condition is also evaluated separately.
View details →Requip
Ropinirole (Requip) is on the FAA's Do Not Issue list. Dopamine agonists are disqualifying whether used for Parkinson's disease, restless legs syndrome, or another condition. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. The underlying condition is also evaluated separately.
View details →Cogentin
Benztropine (Cogentin) is on the FAA's Do Not Issue list among oral anticholinergics used for parkinsonism. An AME cannot issue a medical certificate while you are taking it; clearance from the FAA is required. The condition it treats, including medication-induced movement disorders, is also evaluated separately.
View details →Vuity, Isopto Carpine
The FAA considers pilocarpine eye drops unacceptable. Vuity, prescribed for age-related blurry near vision, works by shrinking the pupil, which can impair night vision and makes your visual acuity depend on ambient lighting. The manufacturer also warns about night driving and operating machinery. Pilocarpine for glaucoma is likewise listed as unacceptable.
View details →Various OTC supplements
The FAA's Do Not Fly table names kava among active dietary supplements that can cause sedation and impair performance even when you feel alert. Do not fly while using it. If you use it routinely, the AME should defer. Supplements aren't FDA-regulated like medications, so tell your AME about any you take.
View details →Various OTC supplements
The FAA's Do Not Fly table names kratom among active dietary supplements that can cause sedation and impair performance even when you feel alert. Do not fly while using it. If you use it routinely, the AME should defer. Supplements aren't FDA-regulated like medications, so tell your AME about any you take.
View details →Various OTC supplements
The FAA's Do Not Fly table names valerian among active dietary supplements that can cause sedation and impair performance even when you feel alert. Do not fly while using it. If you use it routinely, the AME should defer. Supplements aren't FDA-regulated like medications, so tell your AME about any you take.
View details →The U.S. Federal Aviation Administration does not publish a comprehensive list of “approved” medications for pilots. The information in this database represents our interpretation of publicly available FAA guidance documents including the AME Guide, Do-Not-Issue/Do-Not-Fly tables, and related Advisory Circulars. It is provided for informational and educational purposes only.
FAR regulations (61.53, 67.113, 67.213, 67.313, and 91.17) prohibit exercising pilot privileges while using any medication or substance that affects your faculties in a way contrary to safety. The primary issue with the FAA is always whether the underlying medical condition — not just the medication — is compatible with safe flight.
This database is not a substitute for consultation with a qualified Aviation Medical Examiner (AME). You should only start, stop, or change medications after consulting with your treating physician. FAA policies are subject to change without notice. ClearedMed is not affiliated with or endorsed by the FAA.